CytoSorbents Corporation (CTSO)

[biotech48]

There is this from Cytosorb regarding liver transplant, it may help.
Summary:
This case study reports on a 50-year-old immunocompetent woman who was admitted to hospital for acute hepatitis with acute liver failure. After transfer to ICU, the patient was diagnosed with hemophagocytic lymphohistiocytosis (HLH) due to herpes simplex virus infection with cytokine storm (IL-6: 81,059 pg/mL; Il-2: 6,815 U/mL; ferritin: 266,000 ug/L)) and rapidly developed MOF and was listed for highly urgent liver transplantation. Since existing liver support techniques (MARS treatment) for bridging to liver transplantation had no effect, SPAD (single pass albumin dialysis) in combination with CytoSorb® was applied, resulting in a marked decrease of IL-6, bilirubin as well as a reduction of vasopressor need. Orthotopic liver transplantation could be successfully performed on the 4th ICU day. CytoSorb® treatment was safe and well-tolerated, without any adverse events occurring. This is an example where CytoSorb® was used to help stabilize and bridge a critically-ill patient with acute, fulminant liver failure to liver transplantation with cytokine storm.

http://cytosorb-therapy.com/case-report/first-description-spad-combined-cytokine-adsorption-fulminant-liver-failure-hemophagocytic-syndrome-due-generalized-hsv-1-infection/